TY - JOUR
T1 - Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis
AU - Watanabe, Naohiro
AU - Taniguchi, Hiroyuki
AU - Kondoh, Yasuhiro
AU - Kimura, Tomoki
AU - Kataoka, Kensuke
AU - Nishiyama, Osamu
AU - Kondo, Masashi
AU - Hasegawa, Yoshinori
N1 - Funding Information:
This study was partly supported by a grant to the Diffuse Lung Diseases Research Group from the Ministry of Health, Labour and Welfare, Japan.
PY - 2014/4
Y1 - 2014/4
N2 - Background: Idiopathic pulmonary fibrosis (IPF) is associated with an independent increased risk of lung carcinogenesis. The benefit of chemotherapy for extensive-stage small-cell lung cancer (ED-SCLC) in cases of IPF remains unknown. This study was conducted to elucidate the efficacy of chemotherapy for ED-SCLC in patients with IPF. Methods: This was a retrospective observational study of ED-SCLC patients with IPF (all with distant metastasis) who received systemic chemotherapy. The response rate, toxicity, overall survival, and progression-free survival (PFS) were investigated. Results: Eleven patients treated with chemotherapy between January 2005 and December 2011 were the subjects of this study. The overall response rate with the 1st regimen was 63.6 %. The median overall survival was 7.0 months, and the median PFS was 4.7 months. Conclusion: Our results suggest that ED-SCLC patients with IPF may benefit from chemotherapy. A prospective study will be needed to confirm this in the future.
AB - Background: Idiopathic pulmonary fibrosis (IPF) is associated with an independent increased risk of lung carcinogenesis. The benefit of chemotherapy for extensive-stage small-cell lung cancer (ED-SCLC) in cases of IPF remains unknown. This study was conducted to elucidate the efficacy of chemotherapy for ED-SCLC in patients with IPF. Methods: This was a retrospective observational study of ED-SCLC patients with IPF (all with distant metastasis) who received systemic chemotherapy. The response rate, toxicity, overall survival, and progression-free survival (PFS) were investigated. Results: Eleven patients treated with chemotherapy between January 2005 and December 2011 were the subjects of this study. The overall response rate with the 1st regimen was 63.6 %. The median overall survival was 7.0 months, and the median PFS was 4.7 months. Conclusion: Our results suggest that ED-SCLC patients with IPF may benefit from chemotherapy. A prospective study will be needed to confirm this in the future.
UR - https://www.scopus.com/pages/publications/84899988574
UR - https://www.scopus.com/pages/publications/84899988574#tab=citedBy
U2 - 10.1007/s10147-013-0554-5
DO - 10.1007/s10147-013-0554-5
M3 - Article
C2 - 23592279
AN - SCOPUS:84899988574
SN - 1341-9625
VL - 19
SP - 260
EP - 265
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
IS - 2
ER -
